SOT Virtual Meeting Program: April 30—Organ to Silicon Chip

Join your SPS Colleagues during the SOT Virtual Meeting Program webinar on April 30

In light of the 2020 SOT Annual Meeting cancellation, SOT is presenting Scientific Sessions and Continuing Education courses as live webinars through May.  Webinars are open to everyone and free, however registration is necessary.

Virtual Meeting Program.png

Organ to Silicon Chip: Emerging In Vitro and In Silico Tools for Evaluation of Cardiotoxicity


Chair(s): Anthony Bahinski, GlaxoSmithKline plc; and Megan McCain, University of Southern California.

Primary Endorser: Cardiovascular Toxicology Specialty Section

Other Endorser(s): In Vitro and Alternative Methods Specialty Section and Drug Discovery Toxicology Specialty Section

There is a crucial need for new technologies that can quickly and reliably predict cardiovascular safety in humans due to drug and environmental exposure. Development of safe and effective drugs is currently hampered by the poor predictive power of existing preclinical models that often lead to failure of drug compounds late in their development, after they enter human clinical trials. Given the tremendous cost of drug development and the long timelines involved, as well as the need for evaluation of emerging environmental pollutants, the development of new technologies such as in silico platforms and novel in vitro platforms have the potential to provide more translational and human predictive models for cardiac toxicity. This Symposium will highlight innovative approaches to developing much-needed new toxicological methods for evaluation of cardiotoxicity beyond electrophysiology and arrhythmia. This Symposium brings together key experts from the fields of machine learning and artificial intelligence, microphysiological systems/organ-on-chips, and engineered cardiac tissues/precision medicine. They will highlight and discuss the advantages and challenges inherent in new innovative tools being applied toward identification and characterization of cardiotoxicity, in healthy and disease states, in pharmaceutical development and environmental safety.

Introduction. Anthony Bahinski, GlaxoSmithKline plc, Collegeville, PA.

Novel Platforms to Interrogate Cardiac Physiology and Drug-Induced Changes in Contractility Using hiPSc-CM. Khuram Chaudhary, GlaxoSmithKline plc, Collegeville, PA.

Engineering Functional Cardiac Microtissues for Human Disease Modeling and Drug Screening. Megan McCain, University of Southern California, Los Angeles, CA.

Cardiac Contractility In Vitro: From Patient-Specific to Air Pollution Studies. Anna Grosberg, University of California Irvine, Irvine, CA.

Using Weighted Gene Coregulation Network Analysis (WGCNA) to Decipher Temporal Dynamics in Cardiotoxicity. Arif Rahman, NIEHS/NTP, Morrisville, NC.

Evaluation of In Vitro Structural Cardiotoxicity Using Deep Neural Networks. Mahnaz Maddah, Dana Solutions LLC, Palo Alto, CA.

Registration is required.

Recent Stories
ICH E14 and S7B: Webinar on the Recently Released Draft Q&As

Still Deciding? 4 Reasons to Attend #SPSVirtual2020

Join Us Online Aug. 27 - Chronobiology: An overview highlighting opportunities and obstacles for pharmacology